Adverse Drug Reactions - Analysis and Consulting (ADR-AC) GmbH, Bern, Switzerland.
Clin Exp Allergy. 2010 Feb;40(2):257-68. doi: 10.1111/j.1365-2222.2009.03425.x. Epub 2009 Dec 16.
One to three percent of patients exposed to intravenously injected iodinated contrast media (CM) develop delayed hypersensitivity reactions. Positive patch test reactions, immunohistological findings, and CM-specific proliferation of T cells in vitro suggest a pathogenetic role for T cells. We have previously demonstrated that CM-specific T cell clones (TCCs) show a broad range of cross-reactivity to different CM. However, the mechanism of specific CM recognition by T cell receptors (TCRs) has not been analysed so far.
To determine how T cells specifically recognize CM.
CM-specific TCCs were generated from human blood of three CM-allergic patients and a specific TCR was transfected into a mouse T cell hybridoma. Functional analysis such as proliferation assays, IL-2 secretion assays, and calcium influx experiments were performed using irradiated, glutaraldehyde-fixed, CM-pre-incubated, human leucocyte antigen (HLA)-DR-matched or -mismatched antigen-presenting cells (APCs), and HLA-blocking antibodies.
We identified two mechanisms of T cell stimulation: some TCCs and the transfectant reacted to CM independent of uptake by APCs because proliferation/IL-2 secretion occurred in the presence of glutaraldehyde-fixed APCs, and intracellular calcium increased within seconds after drug addition. Other TCCs required functional APCs, compatible with uptake and presentation of CM on MHC-class II molecules, as implied by three findings: (1) glutaraldehyde fixation of APCs abrogated presentation; (2) CM could not be washed away from CM-pre-incubated APCs; and (3) the optimal pulsing time was 10-20 h. Because allogeneic, MHC-matched, CM-pulsed APCs could induce proliferative responses as well, the ability of CM uptake and presentation is not unique to APCs from patients with CM-induced delayed hypersensitivity.
Our data suggest that CM may be stimulatory for T cells either by direct binding to the MHC-TCR complex or by binding after uptake and processing by APCs. This questions the assumed inert nature of CM.
有 1%至 3%的接受静脉注射含碘造影剂(CM)的患者会发生迟发性超敏反应。阳性斑贴试验反应、免疫组织化学发现以及体外 CM 特异性 T 细胞增殖表明 T 细胞起致病作用。我们之前已经证明,CM 特异性 T 细胞克隆(TCC)对不同 CM 表现出广泛的交叉反应。然而,迄今为止,尚未分析 T 细胞受体(TCR)特异性识别 CM 的机制。
确定 T 细胞如何特异性识别 CM。
从 3 名 CM 过敏患者的血液中生成 CM 特异性 TCC,并将特异性 TCR 转染到小鼠 T 细胞杂交瘤中。使用照射、戊二醛固定、CM 预孵育、HLA-DR 匹配或不匹配的抗原呈递细胞(APC)以及 HLA 阻断抗体进行增殖测定、IL-2 分泌测定和钙内流实验等功能分析。
我们确定了两种 T 细胞刺激机制:一些 TCC 和转染体对 CM 无 APC 摄取反应,因为在戊二醛固定 APC 存在的情况下发生增殖/IL-2 分泌,并且在药物添加后几秒钟内细胞内钙增加。其他 TCC 需要功能正常的 APC,这与 CM 在 MHC Ⅱ类分子上的摄取和呈递相容,这由以下三个发现暗示:(1)APC 的戊二醛固定可消除呈递;(2)CM 不能从 CM 预孵育的 APC 中洗掉;(3)最佳脉冲时间为 10-20 小时。因为同种异体、MHC 匹配、CM 脉冲的 APC 也可以诱导增殖反应,所以 CM 摄取和呈递的能力并不是 CM 诱导迟发性超敏反应患者 APC 所特有的。
我们的数据表明,CM 可能通过直接与 MHC-TCR 复合物结合或通过 APC 摄取和加工后结合而对 T 细胞具有刺激性。这对 CM 被认为是惰性的假设提出了质疑。